Meet Acumetis at WODC US!

Connect with our GVA team

June 9 – 11, 2026 | Boston, USA

Acumetis will be attending WODC US 2026 in Boston. Our Global Value & Access (GVA) team will be on-site to connect with industry leaders and discuss the evolving challenges of pricing, reimbursement, and patient access for orphan and rare disease therapies.

Navigating access in orphan drugs

Bringing orphan therapies to patients presents a distinct set of challenges. Small patient populations, limited clinical evidence, and high unmet need require a different approach to value and access strategy.

Global Value & Access teams must translate complex and often uncertain evidence into clear, credible strategies that support pricing, reimbursement, and timely patient access.

This goes beyond developing value narratives. It requires alignment across evidence generation, stakeholder engagement, and access strategy to ensure that decisions are grounded, defensible, and practical in real-world settings.

Acumetis supports teams in connecting the full value pathway – from early evidence planning through to pricing, reimbursement, and access execution – ensuring clarity, alignment, and confidence at each stage.

We partner with life science organizations to translate clinical and real-world evidence into decision-relevant strategies that support successful access outcomes for rare disease therapies.

Key areas of focus

At WODC US, our discussions will center on:

• Aligning evidence generation strategies for small and heterogeneous patient populations
• Developing robust value narratives in the context of limited clinical and real-world evidence
• Supporting pricing and reimbursement strategies for high-cost, low-volume therapies
• Navigating payer uncertainty and evolving expectations for orphan drugs
• Exploring innovative access approaches, including managed entry and outcomes-based agreements
• Integrating patient and advocacy perspectives into value and access strategy
• Strengthening cross-functional alignment across GVA, Medical, and Commercial teams

Where to Find Us

Acumetis is proud to sponsor the Chill and Charge Zone at WODC US 2026.

You’ll find our team there throughout the conference – whether you’re looking to recharge, take a break, or have a conversation about your current challenges in orphan drug value and access.

About Acumetis

Acumetis partners with life sciences organizations to navigate complex strategic, scientific, and commercial challenges across the product lifecycle.

We bring together medical, access, commercial, insights, and patient strategy into a coordinated path forward, building the knowledge and clarity that strengthen decision-making.

Our work spans Medical Affairs, Market Access, and Commercial Strategy, supporting teams in connecting evidence, engagement, and execution to drive meaningful outcomes.

At the core of our approach is a focus on reframing challenges, bringing strategic clarity, and creating critical connections that enable progress in practice.

Who You’ll Meet

Chris Grimes-Crompton
Partner, Global Value and Access

Chris brings 30+ years of global experience across biotechnology, pharmaceuticals, and healthtech. He has worked on developing and successfully commercialising innovative therapies -bringing more than 20 major medicines and innovations to market across a wide range of therapeutic areas, including oncology, nephrology, hepatitis B & C, respiratory, cardiovascular, gastroenterology, neurology, and NASH.

Schedule a meeting with the Acumetis team by contacting them directly.